Trial abstract · §2
GHRP2-JP-DIAGNOSTIC — design and population
Design, allocation, arms and the population enrolled.
§2Design and population
§2.1Design and allocation
- Design class
- Diagnostic accuracy study of a stimulation test
- Masking
- Assessor-blinded
- Arms
- 2
- Allocation
- Randomised between the intervention and its comparator
- Endpoint adjudication
- Not applicable to the primary endpoint of this design
- Data monitoring
- As specified in the protocol
§2.2Arms
Table 2. Randomised arms. Illustrative: arm-level allocations are reconstructed by the Institute from the design class and the randomised total where the published report does not state them.
| Arm | Allocated | Share | Description |
|---|---|---|---|
| GHRP-2 | — | — | Intervention at the dose reached after titration |
| Placebo | — | — | Matched placebo, administered on the same schedule |
| The randomised total is not recorded by the Institute and arm-level figures are therefore not presented. | |||
§2.3Population
Indication. Growth hormone deficiency and growth-hormone secretagogue pharmacology
Insufficient endogenous growth-hormone secretion, or the pharmacological stimulation of the growth-hormone axis, assessed here principally through provocative testing and IGF-1 response.
Geographic footprint. Canada · Germany · New Zealand · Argentina.
§2.4Eligibility as the Institute reads it
- Included. Insufficient endogenous growth-hormone secretion, or the pharmacological stimulation of the growth-hormone axis, assessed here principally through provocative testing and IGF-1 response.
- Excluded. Participants for whom the intervention is contraindicated, including as stated in the japanese labelling for the diagnostic indication. Exclusion criteria narrow the population to which the estimate applies and are the principal source of indirectness where a trial estimate is applied to ordinary practice.
Compound Evidence Institute · CEI-TR-0106/2 · https://compoundevidence.com/trials/ghrp2-jp-diagnostic/design/ · retrieved 30 July 2026